S&P 500
7,453.20
+1.30%
Dow Jones
52,304.60
+0.69%
Nasdaq 100
29,799.80
+2.47%
Russell 2000
3,014.90
+0.32%
FTSE 100
10,540.20
+0.33%
Nikkei 225
70,699.80
+1.44%
Intellia Therapeutics

Intellia Therapeutics (NTLA) Q2 2026 Earnings

Reported May 11, 2026 at 7:36 AM ET · SEC Source

Q2 26 EPS

$-0.81

BEAT +9.81%

Est. $-0.90

Q2 26 Revenue

$15.0M

BEAT +8.99%

Est. $13.8M

vs S&P Since Q2 26

+17.2%

BEATING MARKET

NTLA +17.5% vs S&P +0.2%

Market Reaction

Did NTLA Beat Earnings? Q2 2026 Results

Intellia Therapeutics delivered a beat on both the top and bottom lines in Q1 2026, extending its EPS beat streak to four consecutive quarters as the gene editing company navigated a pivotal transition toward commercialization. The company posted a l… Read more Intellia Therapeutics delivered a beat on both the top and bottom lines in Q1 2026, extending its EPS beat streak to four consecutive quarters as the gene editing company navigated a pivotal transition toward commercialization. The company posted a loss of $0.81 per share, ahead of the $0.90 consensus estimate by 9.81%, while revenue of $15.05 million cleared expectations by 8.99%, even as collaboration revenue slipped 9.5% year-over-year from $16.63 million. The primary financial driver was a sharp pullback in R&D spending to $80.74 million from $108.43 million a year ago, reflecting lower costs for research materials and contracted services, which helped narrow the net loss to $96.23 million from $114.33 million. The quarter's defining moment, however, was clinical: Phase 3 HAELO topline data showed lonvo-z reduced hereditary angioedema attacks by 87% versus placebo, prompting a rolling BLA submission with the FDA and a targeted U.S. Launch in the first half of 2027. With cash of $517.25 million supplemented by an April equity raise of approximately $207 million, management expects to fund operations into 2028, though some analysts have flagged dilution concerns from that offering.

Key Takeaways

  • • Reduced R&D expenses due to lower costs for research materials, contracted services, employee-related expenses, and stock-based compensation
  • • Increased G&A expenses from commercial infrastructure buildout and higher legal expenses ahead of lonvo-z launch

NTLA Forward Guidance & Outlook

Intellia expects to complete its BLA submission for lonvo-z in the second half of 2026, targeting a U.S. commercial launch in the first half of 2027. The company plans to complete patient enrollment in MAGNITUDE-2 (nex-z for ATTRv-PN) in the second half of 2026. Including proceeds from an April 2026 underwritten public offering of approximately $207 million in gross proceeds, existing cash resources are expected to fund operations at least into 2028, well beyond the anticipated lonvo-z U.S. launch, excluding potential commercial revenues.

24/7 Wall St

NTLA YoY Financials

Q2 2026 vs Q2 2025, source: SEC Filings

24/7 Wall St

NTLA Revenue by Segment

With YoY comparisons, source: SEC Filings

Q3 25 Q2 26

“It has been a remarkable start to 2026 for Intellia. With lonvo-z, we achieved a historic milestone by presenting the world's first Phase 3 data for an in vivo gene editing candidate and initiated a rolling BLA submission as we seek to provide a highly differentiated one-time treatment option to people living with HAE. We also recently resumed patient screening for both of our Phase 3 clinical trials in ATTR and strengthened our balance sheet with an underwritten public offering. We look forward to achieving additional important milestones during the remainder of the year.”

— John Leonard, Q2 2026 Earnings Press Release

Back to NTLA Stock Page